English | Español

Biospace
+ Pharmaceuticals
Patient Daily | Aug 7, 2026

Vistagen’s anxiety nasal spray fails to outperform placebo in Phase 2 study
+ Pharmaceuticals
Patient Daily | Aug 7, 2026

Intellia links liver safety signals in ATTR gene therapy to specific HLA allele
+ Pharmaceuticals
Patient Daily | Aug 7, 2026

Replimune receives FDA approval for Tudriqev in advanced melanoma after previous rejections
+ Pharmaceuticals
Patient Daily | Aug 7, 2026

Biopharma job postings rise in Q2 2026 as layoffs decrease, report shows
+ Pharmaceuticals
Patient Daily | Aug 6, 2026

FDA approves Takeda’s Orzeyful for narcolepsy type 1 treatment
+ Pharmaceuticals
Patient Daily | Aug 6, 2026

Industry leaders discuss differences between CROs and biotechs for career seekers
+ Pharmaceuticals
Patient Daily | Aug 6, 2026

Experts discuss emerging approaches for treatment-resistant depression on podcast episode
+ Pharmaceuticals
Patient Daily | Aug 6, 2026

Moderna receives FDA approval for mRNA-based flu vaccine mFLUVISA

Trending
+ Pharmaceuticals
Patient Daily | Aug 4, 2026

Merck reports mixed results for tulisokibart in recent clinical trials and financial update
+ Pharmaceuticals
Patient Daily | Aug 6, 2026

FDA approves Replimune’s melanoma drug Tudriqev after advisory committee debate
+ Regulatory
M. Y. Bailey | Aug 7, 2026

PhRMA's Zirkelbach: 340B program has changed dramatically with 'little transparency into how patients benefit'
+ Regulatory
M. R. Armstrong | Aug 4, 2026

Public Policy Solutions on 340B: 'The program has enriched big hospital execs'